Quantitative brain microdialysls study on the mechanism of quinolones distribution in the central nervous system

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 784-789

  Ooie, Tsuyoshi ^a   Terasaki, Tetsuya ^b   Suzuki, Hiroshi ^d   Sugiyama, Yuichi ^c  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLEROXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLONE DERIVATIVE; 4 QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; DRUG DISTRIBUTION; EPILEPSY; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; IN VITRO STUDY; METABOLISM;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM; MICRODIALYSIS; RATS;

EID: 0030610838     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. W. Christ: Central nervous system toxicity of quinolones: human and animal findings. J. Antimicrob. Chemother. 26 (Suppl. B), 219-225 (1990).
2. J. S. Wolfson and D. C. Hooper: "Quinolone Antimicrobial Agents." American Society for Microbiology, Washington, D.C., 1989.
3. K. Akahane, M. Sekiguchi, T. Une, and Y. Osada: Structure-epileptogenicity relationship of quinolones with special reference to their interaction with γ-aminobutyric acid receptor sites. Antimicrob. Agents Chemother. 33, 1704-1708 (1989).
4. A receptor inhibition required for quinolone-induced convulsions in mice. J. Antimicrob. Chemother. 34, 737-746 (1994).
5. E. Okezaki, T. Terasaki, M. Nakamura, O. Nagata, H. Kato, and A. Tsuji: Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids. Drug Metab. Dispos. 16, 865-874 (1988).
6. K. Naora, Y. Katagiri, N. Ichikawa, M. Hayashibara, and K. Iwamoto: Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. J. Pharmacol. Exp. Ther. 258, 1033-1037 (1991).
7. N. Ichikawa, K. Naora, M. Hayashibara, Y. Katagiri, and K. Iwamoto: Effect of fenbufen on the entry of new quinolones, norfloxacin and ofloxacin, into the central nervous system in rats. J. Pharm. Pharmacol. 44, 915-920 (1992).
8. H. Sato, E. Okezaki, S. Yamamoto, O. Nagata, H. Kato, and A. Tsuji: Entry of the new quinolone antibacterial agents of ofloxacin and NY-198 into the central nervous system in rats. J. Pharmacobio-Dyn. 11, 386-394 (1988).
9. J. Kawakami, K. Yamamoto, Y. Sawada, and T. Iga: Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J. Pharmacokinet. Biopharm. 22, 207-227 (1994).
10. W. M. Pardridge: Brain metabolism: a perspective from the blood-brain barrier. Physiol. Rev. 63, 1481-1535 (1983).
11. T. Terasaki, Y. Deguchi, Y. Kasama, W. M. Pardridge, and A. Tsuji: Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. Int. J. Pharmaceut. 81, 143-152 (1992).
12. U. Ungerstedt: Measurements of neurotransmitter release by intracranial dialysis. In "Measurement of Neurotransmitter Release In Vivo" (C. A. Marsden, ed.), pp. 81-105. Wiley, New York, 1984.
13. Y. Deguchi, T. Terasaki, S. Kawasaki, and A. Tsuji: Muscle microdialysis as a model study to relate the drug concentration in tissue interstitial fluid and dialysate. J. Pharmacobio-Dyn. 14, 483-492 (1991).
14. T. Ooie, H. Suzuki, T. Terasaki, and Y. Sugiyama: Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs. J. Pharmacol. Exp. Ther. 278, 590-596 (1996).
15. H. Matsushita, H. Suzuki, Y. Sugiyama, Y. Sawada, T. Iga, Y. Kawaguchi, and M. Hanano: Facilitated transport of cefodizime into the rat central nervous system. J. Pharmacol. Exp. Ther. 259, 620-625 (1991).
16. +. J. Cereb. Blood Flow Metab. 11, 398-406 (1991).
17. M. Nakashima, M. Kanamaru, T. Uematsu, A. Takiguchi, A. Mizuno, T. Itaya, F. Kawahara, T. Ooie, S. Saito, H. Uchida, and K. Masuzawa: Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J. Antimicrob. Chemother. 22 (Suppl. D), 133-144 (1988).
18. W. M. Pardridge, J. L. Buciak, and P. M. Friden: Selective transport of antitransferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259, 66-70 (1991).
19. U. Jaehde, M. W. E. Langemeijer, A. G. de Boer, and D. D. Breimer: Cerebrospinal fluid transport and disposition of the quinolones ciprofloxacin and pefloxacin in rats. J. Pharmacol. Exp. Ther. 263, 1140-1146 (1992).
20. K. J. Ullrich, G. Rumrich. C. David, and G. Fritzsch: Bisubstrates: substances that interact with both, renal contraluminal organic anion and organic cation transport systems. II. Zwitterionic substrates: dipeptides. cephalosporins, quinolone-carboxylate gyrase inhibitors and phosphamide thiazine carboxylates; nonionizable substrates: steroid hormones and cyclophosphamides. Eur. J. Physiol. 425, 300-312 (1993).
21. T. Okano, H. Maegawa, K. Inui, and R. Hori: Interaction of ofloxacin with organic cation transport system in rat renal brush-border membranes. J. Pharmacol. Exp. Ther. 255, 1033-1037 (1990).
22. M. T. Simanjuntak, H. Sato, I. Tamai, T. Terasaki, and A. Tsuji: Transport of the new quinolone antibacterial agents of lomefloxacin and ofloxacin by rat erythrocytes, and its relation to the nicotinic acid transport system. J. Pharmacobio-Dyn. 14, 475-481 (1991).
23. A. Tsuji, T. Terasaki, Y. Takabatake, Y. Tenda, I. Tamai, T. Yamashima, S. Moritani, T. Tsuruo, and J. Yamashita: P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51, 1427-1437 (1992).
24. T. Tatsuta, M. Naito, T. Oh-hara, I. Sugawara, and T. Tsuruo: Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267, 20383-20391 (1992).
25. A. Tsuji, I. Tamai, A. Sakata, Y. Tenda, and T. Terasaki: Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46, 1096-1099 (1993).
26. A. H. Schinkel, J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. J. te Riele, A. J. M. Berns, and P. Borst: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
27. K. H. Dykstra, A. Arya, D. M. Arriola, P. M. Bungay, P. F. Morrison, and R. L. Dedrick: Microdialysis study of zidovudine (AZT) transport in rat brain. J. Pharmacol. Exp. Ther. 267, 1227-1236 (1993).
28. K. Takasawa, T. Terasaki, H. Suzuki, and Y. Sugiyama: In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281, 369-375 (1997).
29. K. D. K. Adkison, A. A. Artru, K. M. Powers, and D. D. Shen: Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J. Pharmacol. Exp. Ther. 268, 797-805 (1994).
30. H. Suzuki, T. Terasaki, and Y. Sugiyama: Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Deliv. Rev. in press.
31. U. Jaehde, T. Goto, A. G. de Boer, and D. D. Breimer: Blood-brain barrier transport rate of quinolone antibacterials evaluated in cerebrovascular endothelial cell cultures. Eur. J. Pharmaceut. Sci. 1, 49-55 (1993).
32. K. Maxwell, J. A. Berliner, and P. A. Cancilla: Stimulation of glucose analogue uptake by cerebral microvessel endothelial cells by a product released by astrocytes. J. Neuropathol. Exp. Neurol. 48, 69-80 (1989).
33. W. M. Pardridge, D. Triguero, J. Yang, and P. A. Cancilla: Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253, 884-891 (1990).
34. J. Kehr: A survey on quantitative microdialysis: theoretical models and practical implications. J. Neurosci. Methods 48, 251-261 (1993).
35. S. Menacherry, W. Hubert, and J. B. Justice Jr.: In vivo calibration of microdialysis probes for exogenous compounds. Anal. Chem. 64, 577-583, (1992).
36. I. Jacobson, M. Sandberg, and A. Hamberger: Mass transfer in brain dialysis devices - a new method for the estimation of extracellular amino acids concentration. J. Neurosci. Methods 15, 263-268 (1985).
37. P. Lonnroth, P. A. Jansson, B. B. Fredholm, and U. Smith: Microdialysis of intercellular adenosine concentration in subcutaneous tissue in humans. Am. J. Physiol. 256, E250-E255 (1989).
38. N. Lindefors, G. Amberg, and U. Ungerstedt: Intracerebral microdialysis. I. Experimental studies of diffusion kinetics. J. Pharmacol. Methods 22, 141-156 (1989).
39. K. van Belle, T. Dzeka, S. Sarre, G. Ebinger, and Y. Michotte: In vitro and in vivo microdialysis calibration for the measurement of carbamazepine and its metabolites in rat brain tissue using the internal reference technique. J. Neurosci. Methods 49, 167-173 (1993).
40. P. M. Bungay, P. F. Morrison, and R. L. Dedrick: Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci. 46, 105-119 (1990).
41. J. M. Collins and R. L. Dedrick: Distributed model for drug delivery to CSF and brain tissue. Am. J. Physiol. 245, R303-R310 (1983).
42. M. Ogawa, H. Suzuki, Y. Sawada, M. Hanano, and Y. Sugiyama: Kinetics of active efflux via choroid plexus of β-lactam antibiotics from the CSF into the circulation. Am. J. Physiol. 266, R392-R399 (1994).